Advertisement
Advertisement
August 17, 2014
LeMaitre Acquires Omniflow II Biologic Graft
August 18, 2014—LeMaitre Vascular, Inc. announced that it has acquired Xenotis, the manufacturer and marketer of the Omniflow II biological graft for peripheral bypass and dialysis access. Total consideration for 100% of Xenotis’s shares was $7.7 million.
LeMaitre stated that the Omniflow II vascular graft complements its own XenoSure bovine vascular patch and will be marketed through LeMaitre’s vascular-only sales channel. Omniflow II has been used in approximately 20,000 implants since 1990. Xenotis has earned regulatory approvals for Omniflow II in Europe, Australia, New Zealand, Canada, Brazil, and several other international markets. Xenotis manufactures Omniflow II in its own facility in North Melbourne, Victoria, Australia.
Advertisement
Advertisement
